anafranil 25mg tablet
novartis corporation (malaysia) sdn. bhd. - clomipramine hydrochloride -
anafranil sr 75 mg prolonged-release tablets
zr pharma& gmbh - clomipramine hydrochloride - prolonged-release tablet - 75 milligram(s) - non-selective monoamine reuptake inhibitors; clomipramine
anafranil 10mg coated tablets
pharmaand gmbh taborstrasse 1 1020 vienna , austria - clomipramine hydrochloride - coated tablet - clomipramine hydrochloride 10 mg - psychoanaleptics
anafranil 25mg coated tablets
pharmaand gmbh taborstrasse 1 1020 vienna , austria - clomipramine hydrochloride - coated tablet - clomipramine hydrochloride 25 mg - psychoanaleptics
anafranil 75 mg sustained-release tablets
pharmaand gmbh taborstrasse 1 1020 vienna , austria - clomipramine hydrochloride - prolonged-release tablet - clomipramine hydrochloride 75 mg - psychoanaleptics
apvma limited use permit 81063- chlorantraniliprole & sumitomo samurai systemic insecticide / blueberry / scarab larvae
apvma permit - chlorantraniliprole(200g/l)+clothianidin(500g/kg) - insecticide
apvma open use permit 82103- chlorantraniliprole/ linseed/ heliothis
apvma permit - chlorantraniliprole(350g/kg) - group 28 insecticide
apvma open use permit 81560- chlorantraniliprole/ avocado/ lepidoptera
apvma permit - chlorantraniliprole(350g/kg) - group 28 insecticide
tofranil- imipramine hydrochloride injection, solution
geigy pharmaceuticals - imipramine hydrochloride (unii: bke5q1j60u) (imipramine - unii:ogg85sx4e4) - injection, solution - 25 mg in 2 ml - depression : for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than other depressive states. one to three weeks of treatment may be needed before optimal therapeutic effects are evident. the concomitant use of monoamine oxidase inhibiting compounds is contraindicated. hyperpyretic crises or severe convulsive seizures may occur in patients receiving such combinations. the potentiation of adverse effects can be serious, or even fatal. when it is desired to substitute tofranil in patients receiving a monoamine oxidase inhibitor, as long an interval should elapse as the clinical situation will allow, with a minimum of 14 days. initial dosage should be low and increases should be gradual and cautiously prescribed. the drug is contraindicated during the acute recovery period after a myocardial infarction. patients with a known hypersensitivity to this compound should not be given the drug. the possibility of cross-sensitivity to other dibenzazepine compounds should be k
altacor insecticide
fmc new zealand limited - chlorantraniliprole - chlorantraniliprole 350 g/kg - insecticide